YIELD10 Bioscience (YTENQ) 10-Q 8 Aug 16 2016 Q2 Quarterly report Financial data

DOCUMENT AND ENTITY INFORMATION

DOCUMENT AND ENTITY INFORMATION	6 Months Ended
	Jun. 30, 2016shares
Document and Entity Information
Entity registrant name	METABOLIX, INC.
Entity central index key	1,121,702
Current fiscal year end date	--12-31
Entity filer category	Smaller Reporting Company
Document type	10-Q
Document period end date	Jun. 30, 2016
Document fiscal year focus	2,016
Document fiscal period focus	Q2
Amendment flag	false
Entity common stock, shares outstanding	27,844,260
Entity current reporting status	Yes

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Current Assets:
Cash and cash equivalents	$ 3,708,000	$ 12,269,000
Accounts receivable	310,000	238,000
Due from related party	28,000	146,000
Unbilled receivables	103,000	150,000
Inventory	396,000	379,000
Prepaid expenses and other current assets	622,000	1,668,000
Short-term restricted cash	494,000	494,000
Total current assets	5,661,000	15,344,000
Restricted cash	432,000	125,000
Property and equipment, net	2,577,000	905,000
Other assets	717,000	714,000
Total assets	9,387,000	17,088,000
Current Liabilities:
Accounts payable	1,467,000	120,000
Accrued expenses	1,701,000	3,513,000
Deferred revenue	882,000	277,000
Total current liabilities	4,050,000	3,910,000
Other long-term liabilities	1,195,000	150,000
Total liabilities	5,245,000	4,060,000
Commitments and contingencies (Note 9)
Stockholders’ Equity:
Preferred stock ($0.01 par value per share); 5,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock ($0.01 par value per share); 250,000,000 shares authorized at June 30, 2016 and December 31, 2015; 27,752,176 and 27,331,435 shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively	278,000	273,000
Additional paid-in capital	339,391,000	338,580,000
Accumulated other comprehensive loss	(78,000)	(72,000)
Accumulated deficit	(335,449,000)	(325,753,000)
Total stockholders’ equity	4,142,000	13,028,000
Total liabilities and stockholders’ equity	9,387,000	17,088,000
Cash, Cash Equivalents, and Short-term Investments	$ 3,708,000	$ 12,269,000

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Preferred stock, par value per share (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value per share (in dollars per share)	$ 0.01	$ 0.01
Common stock shares authorized	250,000,000	250,000,000
Common stock, shares issued	26,981,214	22,530,322
Common stock, shares outstanding	26,981,214	22,530,322

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Revenue:
Product revenue	$ 174	$ 113	$ 495	$ 185
Grant revenue	188	470	345	922
License fee and royalty revenue (Note 12)	2,431	161	2,628	282
Total revenue	2,793	744	3,468	1,389
Costs and expenses:
Cost of product revenue	121	90	238	174
Research and development	4,289	4,319	8,621	8,244
Selling, general, and administrative	1,613	2,464	4,340	4,930
Total costs and expenses	6,023	6,873	13,199	13,348
Loss from operations	(3,230)	(6,129)	(9,731)	(11,959)
Other income:
Interest income, net	1	1	4	2
Other income, net	31	55	31	41
Total other income, net	32	56	35	43
Net loss	$ (3,198)	$ (6,073)	$ (9,696)	$ (11,916)
Basic and diluted net loss per share:
Net loss per share	$ (0.12)	$ (0.26)	$ (0.35)	$ (0.52)
Number of shares used in per share calculations:
Basic and diluted (in shares)	27,717,447	23,117,539	27,542,376	22,838,511

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Statement of Comprehensive Income [Abstract]
Net loss:	$ (3,198)	$ (6,073)	$ (9,696)	$ (11,916)
Other comprehensive loss
Change in foreign currency translation adjustment	(2)	(1)	(6)
Total other comprehensive loss	(2)	(1)	(6)
Comprehensive loss	$ (3,200)	$ (6,074)	$ (9,702)	$ (11,922)

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities
Net loss	$ (6,073,000)	$ (9,696,000)	$ (11,916,000)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation		272,000	100,000
Charge for 401(k) company common stock match		232,000	218,000
Stock-based compensation		901,000	894,000
Gain (Loss) on Disposition of Property Plant Equipment	0	31,000
Changes in operating assets and liabilities:
Accounts receivables		(72,000)	(94,000)
Due from related party		118,000	22,000
Unbilled receivables		47,000	74,000
Inventory		(17,000)	31,000
Prepaid expenses and other assets		1,043,000	(875,000)
Accounts payable		1,273,000	(165,000)
Accrued expenses		(2,141,000)	(517,000)
Deferred rent and other long-term liabilities		(150,000)	0
Deferred revenue		605,000	99,000
Net cash used in operating activities		(7,890,000)	(12,129,000)
Cash flows from investing activities
Purchase of property and equipment		(389,000)	(209,000)
Proceeds from Sale of Machinery and Equipment	0	31,000
Change in restricted cash		(307,000)	0
Net cash used by investing activities		(665,000)	(209,000)
Net Cash Provided by (Used in) Financing Activities [Abstract]
Proceeds from Issuance of Private Placement	15,000,000	0
Net Cash Provided by (Used in) Financing Activities, Continuing Operations	15,000,000	0
Effect of exchange rate changes on cash and cash equivalents		(6,000)	(1,000)
Net (decrease) increase in cash and cash equivalents		(8,561,000)	2,661,000
Cash and cash equivalents at beginning of period		12,269,000	20,046,000
Cash and cash equivalents at end of period	22,707,000	3,708,000	22,707,000
Supplemental disclosure of non-cash information:
Purchase of property and equipment included in accounts payable and accrued expenses	$ 178	301,000
Stock Issued During Period, Value, Share-based Compensation, Gross		0	305,000
Lease incentive paid by lessor		1,332,000	0
Private Placement Issuance Costs Incurred During Noncash or Partial Noncash Transaction		0	0
Payments Related to Tax Withholding for Share-based Compensation		$ (274,000)	$ 0

BASIS OF PRESENTATION

BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION The accompanying condensed consolidated financial statements are unaudited and have been prepared by Metabolix, Inc. (the “Company”) in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements have been condensed or omitted. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. The consolidated financial statements, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position and results of operations for the interim periods ended June 30, 2016 and 2015 . The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for any future period or the entire fiscal year. These interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2015 , which are contained in the Company’s Annual Report on Form 10-K filed with the SEC on March 29, 2016. The accompanying condensed consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. However, with the exception of 2012, when the Company recognized $38,885 of deferred revenue from a terminated joint venture, it has recorded losses since its inception, including for the fiscal quarter ended June 30, 2016 . As of June 30, 2016 , the Company held unrestricted cash and cash equivalents of $3,708 . The Company has an agreement with Aspire Capital Fund, LLC ("Aspire"), under which Aspire has committed to purchase up to $20,000 of Metabolix’s common stock over a 30 month period that began on November 9, 2015. The purchase agreement contains limitations on the number of shares that the Company may sell to Aspire. Additionally, the Company and Aspire may not effect any sales of shares of the Company's common stock under the purchase agreement during the continuance of an event of default or on any trading day that the closing sale price of its common stock is less than $0.50 per share. At June 30, 2016, the full $20,000 remained available under the purchase agreement with Aspire, although market conditions may limit the extent to which the Company can draw on this facility. The Company’s present capital resources are not sufficient to fund its planned operations for a twelve month period and, therefore, raise substantial doubt about its ability to continue as a going concern. The Company is implementing a strategic restructuring under which Yield10 Bioscience will become its core business with a focus on developing disruptive technologies for step-change improvements in crop yield to enhance global food security. The Company is actively engaged in efforts to secure additional capital resources in August to support the implementation of its new Yield10-focused strategy. All forms of financing may be considered, including public and private equity financing, secured or unsecured debt financing, equity or debt bridge financing, as well as licensing or other collaborative arrangements. In connection with its announced restructuring, the Company initiated actions during July 2016 to significantly reduce its workforce and has ceased pilot biopolymer production in an effort to significantly reduce its ongoing cash burn rate. In addition, the Company is holding its biopolymer assets for sale and may sell or license all or portions of its biopolymer inventory, equipment and intellectual property in connection with its ongoing financing efforts and the implementation of its new strategy. There can be no assurance that these efforts will be successful. If the Company is not able to secure such additional capital resources or otherwise fund its operations, it will be forced to wind down its remaining operations, including the Yield10 program, and pursue options for liquidating the Company's remaining assets, including intellectual property and equipment. The Company continues to face significant challenges and uncertainties. The Company’s future revenues, expenses and cash usage will depend on the completion of the strategic restructuring. Adequate financing to complete the restructuring and implement the new strategy may not be available. Available capital resources may be consumed more rapidly than currently expected due to (a) higher restructuring costs than anticipated; (b) lower than expected revenues from grants, licenses, and service fees related to the Yield10 technologies; (c) changes the Company may make to the business that affect ongoing operating expenses; (d) changes the Company may make to its business strategy; (e) changes in the Company's research and development spending plans; and (f) other items affecting the Company's forecasted level of expenditures and use of cash resources. If the Company issues equity or debt securities to raise additional funds, (i) the Company may incur fees associated with such issuance, (ii) its existing stockholders may experience dilution from the issuance of new equity securities, (iii) the Company may incur ongoing interest expense and be required to grant a security interest in Company assets in connection with any debt issuance, and (iv) the new equity or debt securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. In addition, utilization of the Company’s net operating loss and research and development credit carryforwards may be subject to significant annual limitations under Section 382 of the Internal Revenue Code of 1986 due to ownership changes resulting from equity financing transactions. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products or proprietary technologies, or grant licenses on terms that are not favorable to the Company. On June 30, 2016, the Company received a Notice of Delisting from The Nasdaq Stock Market LLC as a result of the Company's bid price for the previous 30 consecutive business closing below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided with an initial period of 180 calendar days, or until December 27, 2016, to regain compliance. To regain compliance, the closing bid price of the Company's common stock must be $1.00 per share or more for a minimum of 10 consecutive business days at any time before December 27, 2016. If the Company does not regain compliance by December 27, 2016, it may be eligible for an additional 180 calendar day compliance period. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary, subject to Nasdaq's agreement that such an action by the Company would cure the deficiency. The condensed consolidated financial statements do not include any adjustments that may result from the outcome of these uncertainties.

ACCOUNTING POLICIES

ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
ACCOUNTING POLICIES	ACCOUNTING POLICIES There have been no material changes in accounting policies since the Company’s fiscal year ended December 31, 2015 , as described in Note 2 to the consolidated financial statements included in its Annual Report on Form 10-K for the year then ended. Principles of Consolidation The Company's consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions were eliminated, including transactions with its Canadian subsidiary, Metabolix Oilseeds, Inc. Restructuring The Company's policy is to record restructuring charges using estimates of cash expenditures for contract termination costs and employee post-termination benefits. The Company also records non-cash accelerated depreciation charge for any related equipment and leasehold improvements. Reclassification Certain amounts in prior year financial statements have been reclassified to conform with current year presentation. Reverse Stock Split On May 26, 2015, the Company effected a 1-for-6 reverse stock split of its common stock. Unless otherwise indicated, all share amounts, per share data, share prices, exercise prices, and conversion rates set forth in these notes and the accompanying financial statements have, where applicable, been adjusted retroactively to reflect this reverse stock split. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Foreign Currency Translation Foreign denominated assets and liabilities of the Company's wholly-owned foreign subsidiaries are translated into U.S. dollars at the prevailing exchange rates in effect on the balance sheet date. Revenues and expenses are translated at average exchange rates prevailing during the period. Any resulting translation gains or losses are recorded in accumulated other comprehensive income (loss) in the consolidated balance sheet. When the Company dissolves, sells or substantially sells all of the assets of a consolidated foreign subsidiary, the cumulative translation gain or loss of that subsidiary is released from comprehensive income (loss) and included within its consolidated statement of operations during the fiscal period when the dissolution or sale occurs. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company has historically invested its cash equivalents in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes. Investments, when purchased, are acquired in accordance with the Company’s investment policy which establishes a concentration limit per issuer. At June 30, 2016 , the Company’s cash equivalents are invested solely in money market funds. The Company provides credit to customers in the normal course of business. The Company performs ongoing credit evaluations of its customers’ financial condition and limits the amount of credit extended when deemed necessary. At June 30, 2016 , the Company’s accounts and unbilled receivables include $155 or 35% from U.S. and Canadian government grants.

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	6 Months Ended
	Jun. 30, 2016
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718) : Improvements to Employee Share-Based Payment Accounting. The new standard involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The new standard will be effective for us on January 1, 2017. The Company is in the process of evaluating the impact of this new guidance. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) , which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. ASC 842 supersedes the previous leases standard, ASC 840 Leases. The standard is effective on January 1, 2019, with early adoption permitted. The Company is in the process of evaluating the impact of this new guidance. In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory , which requires entities to measure most inventory “at the lower of cost and net realizable value,” thereby simplifying the current guidance under which an entity must measure inventory at the lower of cost or market. ASU 2015-11 is effective for annual and interim periods beginning after December 15, 2016, with early adoption permitted. The Company is currently reviewing the potential impact of adopting the new guidance. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40) . The new guidance addresses management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern for one year after the date that the financial statements are issued and to provide related footnote disclosures. Management’s evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued. This guidance should reduce diversity in the timing and content of footnote disclosures. The amendments in this update apply to all entities and are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early adoption is permitted. The Company is currently reviewing the potential impact of adopting the new guidance on its current disclosures. In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) , which supersedes all existing revenue recognition requirements, including most industry specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date , which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued ASU No. 2016-10, R evenue from Contracts with Customers (Topic 606) : Identifying Performance Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606) : Narrow-Scope Improvements and Practical Expedients related to disclosures of remaining performance obligations, as well as other amendments to guidance on collectibility, non-cash consideration and the presentation of sales and other similar taxes collected from customers. These standards have the same effective date and transition date of January 1, 2018. The Company is are currently evaluating the method of adoption and the potential impact that these standards may have on its financial position and results of operations.

BASIC AND DILUTED NET INCOME (L

BASIC AND DILUTED NET INCOME (LOSS) PER SHARE	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
BASIC AND DILUTED NET INCOME (LOSS) PER SHARE	BASIC AND DILUTED NET INCOME (LOSS) PER SHARE Basic net income (loss) per share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding. Diluted net income (loss) per share is computed by dividing net loss by the weighted-average number of dilutive common shares outstanding during the period. Diluted shares outstanding is calculated by adding to the weighted shares outstanding any potential (unissued) shares of common stock from outstanding stock options and warrants based on the treasury stock method, as well as weighted shares outstanding of any potential (unissued) shares of common stock from restricted stock units. In periods when a net loss is reported, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced. Therefore, in periods when a loss is reported, there is no difference in basic and dilutive loss per share. Common stock equivalents include stock options, restricted stock awards and warrants. The Company follows the two-class method when computing net loss per share, when it has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participating rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based on their respective rights to receive dividends, as if all income for the period has been distributed or losses to be allocated if they are contractually required to fund losses. There were no amounts allocated to participating securities for the three and six months ended June 30, 2016 and 2015, as the Company was in a loss position and had no shares that met the definition of participating securities outstanding at June 30, 2016 and 2015. On May 26, 2015, the Company effected a 1-for-6 reverse stock split of its common stock. The calculation of basic and diluted net loss per share, as presented in the accompanying condensed consolidated statements of operations, have been determined based on retroactive adjustment of weighted average shares outstanding for all periods presented. The number of shares of potentially dilutive common stock presented on a weighted average basis, related to options, restricted stock units and warrants (prior to consideration of the treasury stock method) that were excluded from the calculation of dilutive shares since the inclusion of such shares would be anti-dilutive for the three and six months ended June 30, 2016 and 2015, respectively, are shown below: Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Options 944,828 937,121 934,403 970,460 Restricted stock units 718,709 1,180,773 948,216 643,372 Warrants 3,933,000 648,297 3,933,000 325,939 Total 5,596,537 2,766,191 5,815,619 1,939,771

INVENTORY

INVENTORY	6 Months Ended
	Jun. 30, 2016
Inventory Disclosure [Abstract]
INVENTORY	INVENTORY The components of biopolymer inventories of the Company are as follows: June 30, December 31, Raw materials $ 71 $ 51 Finished goods 325 328 Total inventory $ 396 $ 379 Included within finished goods at June 30, 2016 and December 31, 2015, are $58 and $51 , respectively, of inventory that the Company has sold and shipped to customers for which the Company has not yet recognized revenue under its product revenue recognition policy. On a quarterly basis, the Company uses consistent methodologies to evaluate inventory for net realizable value, reducing the value of inventory for excess and obsolete inventory based upon certain assumptions made about future customer demand, quality and possible alternative uses. The Company recorded no inventory impairment charges to cost of product revenue during the three and six months ended June 30, 2016 and June 30, 2015, for inventory that it determined was unlikely to be sold or was at a lower cost than market. The Company is currently undertaking efforts to monetize its existing inventory in connection with its announced plan to discontinue its biopolymer operations. The Company anticipates that it will be able to sell the inventory at prices in excess of its carrying cost at June 30, 2016. See Note 14.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	6 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS The Company has certain financial assets recorded at fair value which have been classified as Level 1 within the fair value hierarchy as described in the accounting standards for fair value measurements. Fair value is the price that would be received from the sale of an asset or the price paid to transfer a liability in an orderly transaction between independent market participants at the measurement date. Fair values determined by Level 1 inputs utilize observable data such as quoted prices in active markets for identical instruments. Fair values determined by Level 2 inputs utilize data points other than quoted prices in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its own assumptions. The fair value hierarchy level is determined by the lowest level of significant input. At June 30, 2016 and December 31, 2015, the Company did not own any Level 2 or Level 3 financial assets or liabilities and there were no transfers of financial assets or liabilities between category levels. The Company's assets are measured at fair value on a recurring basis. The balance of Level 1 assets as of June 30, 2016 and December 31, 2015 were $3,100 and $11,203 , respectively, and for both periods the assets were invested in money market funds classified in cash and cash equivalents.

ACCRUED EXPENSES

ACCRUED EXPENSES	6 Months Ended
	Jun. 30, 2016
Payables and Accruals [Abstract]
ACCRUED EXPENSES	ACCRUED EXPENSES Accrued expenses consisted of the following at: June 30, December 31, Employee compensation and benefits $ 595 $ 2,114 Commercial manufacturing 13 465 Professional services 370 431 Other 723 503 Total accrued expenses $ 1,701 $ 3,513

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	6 Months Ended
	Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION At June 30, 2016 , there was approximately $2,858 of pre-tax stock-based compensation expense, net of estimated forfeitures, related to unvested awards not yet recognized. Employee, Non-employee and Director Stock Options The Company recognized stock-based compensation expense related to stock option awards of $310 and $901 for the three and six months ended June 30, 2016, respectively. The Company recognized stock-based compensation expense related to stock option awards of $578 and $891 for the three and six months ended June 30, 2015, respectively. During the three months ended June 30, 2016, the Company reduced its stock compensation expense by $87 as a result of known stock awards that will be forfeited in connection with the Company's restructuring announced in July 2016. The compensation expense related to unvested stock options is expected to be recognized over a remaining weighted average period of 1.60 years. A summary of option activity for the six months ended June 30, 2016 is as follows: Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2015 904,133 $ 26.58 Granted 55,000 1.34 Exercised — — Forfeited (808 ) 5.97 Expired (13,315 ) 38.20 Outstanding at June 30, 2016 945,010 $ 24.97 Options exercisable at June 30, 2016 677,609 $ 32.31 Restricted Stock Units On January 2, 2014, the Company awarded 100,000 restricted stock units ("RSUs") to its Chief Executive Officer. These restricted stock units contained both market and performance conditions which were based on the achievement of certain stock price and revenue targets, respectively. The restricted stock units would have vested in various percentages over three years (subject to certain accelerated and continued vesting events) once the agreed-upon stock price and/or revenue based targets were achieved. Neither the market nor performance conditions were met by January 2, 2016 resulting in the restricted stock units being forfeited as of that date. In accordance with accounting guidance for stock compensation, the amortization of these restricted stock units will continue through March 2018. During 2015, the Company began using RSUs as a broad-based form of long-term compensation incentive for its officers, directors and employees. On April 1, 2015, the Company awarded 203,967 RSUs under the 2014 Plan to members of senior management pursuant to elections previously made by the senior managers to convert a portion of their 2014 performance bonuses from cash to equity. These RSUs vested one year from the date of grant. During the year ended December 31, 2015, the Company also awarded a total of 906,806 additional long-term incentive RSUs to senior managers and employees. These RSUs vest in four equal annual installments beginning one year after the date of grant, subject to service conditions. On September 10, 2015, the Company awarded 81,250 RSUs to its non-employee directors. These RSUs vested on May 28, 2016. No RSUs were awarded by the Company during the six months ending June 30, 2016. The Company records stock compensation expense for RSUs on a straight line basis over their vesting period based on each RSU's award date market value. The Company recognizes compensation expense for only the portion of awards that are expected to vest based on forfeiture estimates. In developing a forfeiture rate estimate, the Company considered its historical experience and actual forfeitures for the year. The Company will continue to evaluate its forfeiture rate as compared to the actual number of forfeitures in future periods to determine if adjustments to compensation expense may be required. The Company pays required minimum federal, state or provincial income tax withholding associated with RSUs for its U.S. and Canadian employees. As the RSUs vest, the Company withholds a number of shares with an aggregate fair market value equal to the minimum tax withholding amount (unless the employee makes other arrangements for payment of the tax withholding) from the common stock issuable at the vest date. During the six months ended June 30, 2016, the Company paid $274 for income tax withholdings associated with RSUs that vested during the period. A summary of RSU activity for the six months ended June 30, 2016 is as follows: Number of RSUs Weighted Average Remaining Contractual Life (years) Outstanding at December 31, 2015 1,286,773 Awarded — Released (454,131 ) Forfeited (113,900 ) Outstanding at June 30, 2016 718,742 1.75 Vested and expected to vest as of June 30, 2016 611,510 1.71 Weighted average remaining recognition period 2.75

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Lease Commitments On January 20, 2016, the Company entered into an agreement with the landlord of its Cambridge, MA facility to terminate the lease effective July 31, 2016. Concurrent with the termination of its Cambridge lease, the Company entered into a lease agreement pursuant to which the Company leases approximately 30,000 square feet of office and research and development space located at 19 Presidential Way, Woburn, Massachusetts. The lease began on June 1, 2016 and will end on November 30, 2026. Annual base rental payments remaining due under the Woburn lease are as follows: Year ended December 31, Minimum lease payment 2016 (July - December) $ 185 2017 725 2018 785 2019 and thereafter 7,346 Total $ 9,041 The Company provided the landlord with a security deposit in the form of a letter of credit in the amount of $307 . Pursuant to the lease, the Company will also pay certain taxes and operating costs associated with the premises during the term of the lease. Under the terms of the lease agreement, the landlord paid $889 for tenant improvements to the facility and an additional $444 for tenant improvements that will result in increased rental payments by the Company. The landlord’s contributions toward the cost of tenant improvements are recorded as short and long-term lease incentive obligation on the Company's consolidated balance sheet. The lease incentive obligation will be amortized to the Company's consolidated statement of operations as reductions to rent expense over the lease term. As of June 30, 2016, the Company has a remaining lease incentive obligation of $1,322 . Contractual Commitments In connection with the Company’s PHA biopolymers program, during May 2015 the Company entered into agreements with a U.S. supplier of toll fermentation services and with the owner/operator of its pilot recovery facility. Under the fermentation services agreement, the Company is obligated to pay fixed toll fermentation service fees of approximately $600 per quarter from February 2016 until July 2017. During May 2015, the Company prepaid $1,000 for these future fermentation services. At June 30, 2016, $167 remains available from this prepayment for offset against future service fees and is included in prepaid expenses and other current assets in the Company's consolidated balance sheet. The Company is currently incurring contractual fixed fees of approximately $520 per quarter for the biopolymer recovery facility that will continue until January 31, 2017. In addition to the fixed charges under these agreements, the Company is obligated to pay certain variable production costs as incurred. As a result of the Company's decision during July 2016 to discontinue its biopolymer operations, no further variable production charges are anticipated under either agreement. Litigation From time to time, the Company may be subject to legal proceedings and claims in the ordinary course of business. The Company is not currently aware of any such proceedings or claims that it believes will have, individually or in the aggregate, a material adverse effect on the business, financial condition or the results of operations. Guarantees As of June 30, 2016 and December 31, 2015, the Company did not have significant liabilities recorded for guarantees. The Company enters into indemnification provisions under various agreements with other companies in the ordinary course of business, typically with business partners, contractors, and customers. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of its activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date Metabolix has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of the indemnifications under these agreements is minimal. Accordingly, the Company has no liabilities recorded for these agreements as of June 30, 2016 and December 31, 2015.

GEOGRAPHIC INFORMATION

GEOGRAPHIC INFORMATION	6 Months Ended
	Jun. 30, 2016
Segment Reporting [Abstract]
GEOGRAPHIC INFORMATION	GEOGRAPHIC INFORMATION The geographic distribution of the Company’s operating revenues and long-lived assets are summarized in the tables below: U.S. Canada Eliminations Total Three Months Ended June 30, 2016: Net revenues from external customers $ 2,793 $ — $ — $ 2,793 Inter-geographic revenues — 215 (215 ) — Net revenues $ 2,793 $ 215 $ (215 ) $ 2,793 Three Months Ended June 30, 2015: Net revenues from external customers $ 744 $ — $ — $ 744 Inter-geographic revenues — 203 (203 ) — Net revenues $ 744 $ 203 $ (203 ) $ 744 Six Months Ended June 30, 2016: Net revenues from external customers $ 3,468 $ — $ — $ 3,468 Inter-geographic revenues — 427 (427 ) — Net revenues $ 3,468 $ 427 $ (427 ) $ 3,468 Six Months Ended June 30, 2015: Net revenues from external customers $ 1,388 $ 1 $ — $ 1,389 Inter-geographic revenues — 402 (402 ) — Net revenues $ 1,388 $ 403 $ (402 ) $ 1,389 Foreign revenue is based on the country in which the Company’s subsidiary that earned the revenue is domiciled. During the three and six months ended June 30, 2016 , revenue earned from the Company’s Camelina grant with the U.S. Department of Energy totaled $142 and $299 , respectively, and represented 5% and 9% of total revenue. During the three and six months ended June 30, 2015, revenue earned from the Company's REFABB grant totaled $347 and $677 , and represented 47% and 49% of total revenue. During the six months ended June 30, 2016 and 2015, no biopolymer customer represented 10% or more of the Company’s total revenues. The geographic distribution of the Company’s long-lived assets is summarized as follows: U.S. Canada Eliminations Total June 30, 2016 $ 2,577 $ — $ — $ 2,577 December 31, 2015 $ 903 $ 2 $ — $ 905

INCOME TAXES

INCOME TAXES	6 Months Ended
	Jun. 30, 2016
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using future enacted tax rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. For the three and six months ended June 30, 2016 and 2015 , the Company did not recognize any tax expense or benefit due to its continued net operating loss position. Due to the uncertainty surrounding the realization of favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against its otherwise recognizable net deferred tax assets. The Company follows the accounting guidance related to income taxes including guidance which addresses accounting for uncertainty in income taxes. This guidance prescribes a threshold for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. It also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosures and transitions. The Company had no amounts recorded for any unrecognized tax benefits as of June 30, 2016 or December 31, 2015 .

RELATED PARTIES

RELATED PARTIES	6 Months Ended
	Jun. 30, 2016
Related Party Transactions [Abstract]
RELATED PARTIES	RELATED PARTIES The Company licenses certain technology to Tepha, Inc., a related party, for use in medical applications. During the three months ended June 30, 2016, the Company entered into an amendment to its license agreement with Tepha, in which the Company received a lump sum payment of $2,000 in consideration for an early buyout of all future royalties under the agreement and for the licensing of two additional production strains and related intellectual property. The Company delivered the two production strains to Tepha during July 2016. The Company recorded $1,580 and $1,778 of license and royalty revenue related to Tepha during the three and six months ended June 30, 2016, respectively. At June 30, 2016, $494 of the $2,000 paid by Tepha under the June 2016 amendment was recorded as deferred revenue pending delivery of the new production strains to Tepha during the Company's third fiscal quarter. During the three and six months ended June 30, 2015, the Company recorded license and royalty revenue from Tepha of $115 and $235 , respectively. As of June 30, 2016 and December 31, 2015, the Company had none and $146 , respectively, of outstanding receivables due from Tepha for royalties. During the three months ended June 30, 2016, the Company entered into a purchase and licensing agreement with a third party in which the Company received a lump sum payment of $1,000 in consideration for certain biopolymer inventory and a non-exclusive license to certain patents owned or controlled by the Company related to polyhydroxyalkanoates, or PHA. Included in the Company's reported license fee and royalty revenue for the three and six months ended June 30, 2016 is $850 in licensing revenue related to this agreement.

CAPITAL STOCK

CAPITAL STOCK	6 Months Ended
	Jun. 30, 2016
Stockholders' Equity Note [Abstract]
CAPITAL STOCK	CAPITAL STOCK Common Stock Issuances On October 7, 2015, the Company entered into a common stock purchase agreement with Aspire Capital. Under terms of the agreement, Aspire committed to purchase up to an aggregate of $20,000 of the Company's common stock over a 30 month period that began on November 9, 2015. Common stock may be sold from time to time at the Company’s direction under pricing formulas based on prevailing market prices around the time of each sale. The purchase agreement contains limitations on the number of shares that the Company may sell to Aspire. Additionally, the Company and Aspire may not effect any sales of shares of the Company's common stock under the purchase agreement during the continuance of an event of default or on any trading day that the closing sale price of its common stock is less than $0.50 per share. Upon execution of the purchase agreement, the Company issued 300,000 shares of its common stock to Aspire with a fair value of $450 , as a commitment fee. In addition, the Company incurred $169 of additional costs in connection with the Aspire facility, which along with the fair value of the common stock has been recorded as deferred equity costs and is included within other assets in the accompanying consolidated balance sheet at June 30, 2016. These costs will be proratably charged to additional paid-in-capital as shares are sold to Aspire. In the event it is determined no additional shares will be sold under the purchase agreement, any deferred equity offering costs will be expensed at such time. At June 30, 2016, the full $20,000 under the purchase agreement remains available for sale to Aspire. On June 19, 2015, the Company completed a private placement of its securities. Proceeds received from the transaction were $14,703 , net of issuance costs of $297 . Investors participating in the transaction purchased a total of 4,370,000 shares of common stock at a price of $3.32 per share and warrants with a purchase price of $0.125 per warrant to purchase up to an aggregate of 3,933,000 additional shares of common stock. The warrants have a four -year term and are immediately exercisable at a price of $3.98 per share. The Company reviewed the accounting guidance for warrants and has determined that the warrants should be recorded as equity within additional paid-in capital. On May 26, 2015, the Company effected a 1-for-6 reverse split of its common stock. The reverse stock split reduced the number of shares of the Company's common stock currently outstanding at the time the reverse split was made effective from approximately 136 million shares to approximately 23 million shares. Proportional adjustments were made to the Company's outstanding stock options and restricted stock units and to the number of shares issued and issuable under the Company's equity compensation plans. The number of authorized shares of the Company's common stock remained at 250 million shares.

SUBSEQUENT EVENT (Notes)

SUBSEQUENT EVENT (Notes)	6 Months Ended
	Jun. 30, 2016
Subsequent Events [Abstract]
Subsequent Events [Text Block]	SUBSEQUENT EVENT On July 20, 2016, the Board of Directors of the Company approved a plan to implement a strategic restructuring under which Yield10 Bioscience will become its core business with a focus on developing disruptive technologies for step-change improvements in crop yield to enhance global food security. As part of the restructuring, Metabolix is discontinuing its biopolymer operations and eliminating approximately 45 positions in its biopolymer operations and corporate organization, and is pursuing the sale of its biopolymers business assets. The Company estimates that it will record restructuring charges of approximately $4,000 during its third fiscal quarter of 2016 related to estimated cash expenditures for contract termination costs and employee post-termination benefits in accordance with ASC 420-10, Exit or Disposal Cost Obligations . The Company is working to minimize cash costs associated with the restructuring. The Company also expects to record a non-cash accelerated depreciation charge of approximately $600 during its third quarter for manufacturing equipment and leasehold improvements related to its discontinued biopolymer operations.

ACCOUNTING POLICIES (Policies)

ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Principles of consolidation	Principles of Consolidation The Company's consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions were eliminated, including transactions with its Canadian subsidiary, Metabolix Oilseeds, Inc.
Use of estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.
Foreign currency translation	Foreign Currency Translation Foreign denominated assets and liabilities of the Company's wholly-owned foreign subsidiaries are translated into U.S. dollars at the prevailing exchange rates in effect on the balance sheet date. Revenues and expenses are translated at average exchange rates prevailing during the period. Any resulting translation gains or losses are recorded in accumulated other comprehensive income (loss) in the consolidated balance sheet. When the Company dissolves, sells or substantially sells all of the assets of a consolidated foreign subsidiary, the cumulative translation gain or loss of that subsidiary is released from comprehensive income (loss) and included within its consolidated statement of operations during the fiscal period when the dissolution or sale occurs.
Concentration of credit risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company has historically invested its cash equivalents in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes. Investments, when purchased, are acquired in accordance with the Company’s investment policy which establishes a concentration limit per issuer. At June 30, 2016 , the Company’s cash equivalents are invested solely in money market funds. The Company provides credit to customers in the normal course of business. The Company performs ongoing credit evaluations of its customers’ financial condition and limits the amount of credit extended when deemed necessary.
Recent accounting pronouncements	RECENT ACCOUNTING PRONOUNCEMENTS In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718) : Improvements to Employee Share-Based Payment Accounting. The new standard involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The new standard will be effective for us on January 1, 2017. The Company is in the process of evaluating the impact of this new guidance. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) , which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. ASC 842 supersedes the previous leases standard, ASC 840 Leases. The standard is effective on January 1, 2019, with early adoption permitted. The Company is in the process of evaluating the impact of this new guidance. In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory , which requires entities to measure most inventory “at the lower of cost and net realizable value,” thereby simplifying the current guidance under which an entity must measure inventory at the lower of cost or market. ASU 2015-11 is effective for annual and interim periods beginning after December 15, 2016, with early adoption permitted. The Company is currently reviewing the potential impact of adopting the new guidance. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40) . The new guidance addresses management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern for one year after the date that the financial statements are issued and to provide related footnote disclosures. Management’s evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued. This guidance should reduce diversity in the timing and content of footnote disclosures. The amendments in this update apply to all entities and are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early adoption is permitted. The Company is currently reviewing the potential impact of adopting the new guidance on its current disclosures. In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) , which supersedes all existing revenue recognition requirements, including most industry specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date , which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued ASU No. 2016-10, R evenue from Contracts with Customers (Topic 606) : Identifying Performance Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606) : Narrow-Scope Improvements and Practical Expedients related to disclosures of remaining performance obligations, as well as other amendments to guidance on collectibility, non-cash consideration and the presentation of sales and other similar taxes collected from customers. These standards have the same effective date and transition date of January 1, 2018. The Company is are currently evaluating the method of adoption and the potential impact that these standards may have on its financial position and results of operations.

BASIC AND DILUTED NET INCOME 22

BASIC AND DILUTED NET INCOME (LOSS) PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Schedule of number of shares of potentially dilutive common stock related to options and warrants that were excluded from the calculation of dilutive shares	The number of shares of potentially dilutive common stock presented on a weighted average basis, related to options, restricted stock units and warrants (prior to consideration of the treasury stock method) that were excluded from the calculation of dilutive shares since the inclusion of such shares would be anti-dilutive for the three and six months ended June 30, 2016 and 2015, respectively, are shown below: Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Options 944,828 937,121 934,403 970,460 Restricted stock units 718,709 1,180,773 948,216 643,372 Warrants 3,933,000 648,297 3,933,000 325,939 Total 5,596,537 2,766,191 5,815,619 1,939,771

INVENTORY (Tables)

INVENTORY (Tables)	6 Months Ended
	Jun. 30, 2016
Inventory Disclosure [Abstract]
Schedule of the components of the Company's biopolymer inventories	The components of biopolymer inventories of the Company are as follows: June 30, December 31, Raw materials $ 71 $ 51 Finished goods 325 328 Total inventory $ 396 $ 379

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	6 Months Ended
	Jun. 30, 2016
Payables and Accruals [Abstract]
Schedule of accrued expenses	Accrued expenses consisted of the following at: June 30, December 31, Employee compensation and benefits $ 595 $ 2,114 Commercial manufacturing 13 465 Professional services 370 431 Other 723 503 Total accrued expenses $ 1,701 $ 3,513

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	6 Months Ended
	Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of option activity	A summary of option activity for the six months ended June 30, 2016 is as follows: Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2015 904,133 $ 26.58 Granted 55,000 1.34 Exercised — — Forfeited (808 ) 5.97 Expired (13,315 ) 38.20 Outstanding at June 30, 2016 945,010 $ 24.97 Options exercisable at June 30, 2016 677,609 $ 32.31
Schedule of restricted stock units activity	A summary of RSU activity for the six months ended June 30, 2016 is as follows: Number of RSUs Weighted Average Remaining Contractual Life (years) Outstanding at December 31, 2015 1,286,773 Awarded — Released (454,131 ) Forfeited (113,900 ) Outstanding at June 30, 2016 718,742 1.75 Vested and expected to vest as of June 30, 2016 611,510 1.71 Weighted average remaining recognition period 2.75

GEOGRAPHIC INFORMATION (Tables)

GEOGRAPHIC INFORMATION (Tables)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Segment Reporting [Abstract]
Schedule of the geographic distribution of revenues and long-lived assets from continuing operations		The geographic distribution of the Company’s operating revenues and long-lived assets are summarized in the tables below: U.S. Canada Eliminations Total Three Months Ended June 30, 2016: Net revenues from external customers $ 2,793 $ — $ — $ 2,793 Inter-geographic revenues — 215 (215 ) — Net revenues $ 2,793 $ 215 $ (215 ) $ 2,793 Three Months Ended June 30, 2015: Net revenues from external customers $ 744 $ — $ — $ 744 Inter-geographic revenues — 203 (203 ) — Net revenues $ 744 $ 203 $ (203 ) $ 744 Six Months Ended June 30, 2016: Net revenues from external customers $ 3,468 $ — $ — $ 3,468 Inter-geographic revenues — 427 (427 ) — Net revenues $ 3,468 $ 427 $ (427 ) $ 3,468 Six Months Ended June 30, 2015: Net revenues from external customers $ 1,388 $ 1 $ — $ 1,389 Inter-geographic revenues — 402 (402 ) — Net revenues $ 1,388 $ 403 $ (402 ) $ 1,389
Schedule of the geographic distribution of long-lived assets	The geographic distribution of the Company’s long-lived assets is summarized as follows: U.S. Canada Eliminations Total June 30, 2016 $ 2,577 $ — $ — $ 2,577 December 31, 2015 $ 903 $ 2 $ — $ 905

BASIS OF PRESENTATION (Details)

BASIS OF PRESENTATION (Details) - USD ($)	Oct. 07, 2015	Jun. 30, 2015	Jun. 30, 2016
Other Commitments [Line Items]
Deferred revenue recognized from the terminated Telles joint venture		$ 38,885,000
Unrestricted cash, cash equivalents and investments			$ 3,708,000
Period over which company's present capital resources are not sufficient to fund its planned operations			12 months
Private Placement [Member] | Aspire [Member]
Other Commitments [Line Items]
Term of contractual service agreement	30 months
Other Commitment	$ 20,000,000

ACCOUNTING POLICIES (Details)

ACCOUNTING POLICIES (Details) - Accounts receivable - Credit concentration risk - US, Canadian, and German government grants $ in Thousands	6 Months Ended
	Jun. 30, 2016USD ($)
Concentration of credit risk
Accounts receivable	$ 155
Receivables/Sales (as a percent)	35.00%

BASIC AND DILUTED NET INCOME 29

BASIC AND DILUTED NET INCOME (LOSS) PER SHARE (Details)	May 26, 2015shares	Jun. 30, 2016shares	Jun. 30, 2015shares	Jun. 30, 2016shares	Jun. 30, 2015shares	Dec. 31, 2015shares
Antidilutive securities
Preferred stock, shares outstanding		0		0		0
Antidilutive common stock excluded from the calculation of dilutive shares		5,596,537	2,766,191	5,815,619	1,939,771
Preferred shares issued		0		0		0
Common stock conversion ratio for each preferred stock	0.1667
Common stock shares authorized	250,000,000	250,000,000		250,000,000		250,000,000
Options
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares		944,828	937,121	934,403	970,460
Restricted stock units
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares		718,709	1,180,773	948,216	643,372
Warrants
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares		3,933,000	648,297	3,933,000	325,939

INVENTORY (Details)

INVENTORY (Details) - USD ($)	6 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Raw materials	$ 71,000	$ 51,000
Finished goods	325,000	328,000
Total inventory	396,000	379,000
Inventory on which revenue not recognized	58,000	$ 51,000
Charges to cost of product revenue for inventory unlikely to be sold	$ 0

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Fair Value, measurements, recurring | Quoted prices in active markets for identical assets | Money market funds
Fair value measurements
Assets, Fair Value Disclosure	$ 3,100,260	$ 11,202,709

ACCRUED EXPENSES (Details)

ACCRUED EXPENSES (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Payables and Accruals [Abstract]
Employee compensation and benefits	$ 595	$ 2,114
Commercial manufacturing	13	465
Professional services	370	431
Other	723	503
Total accrued expenses	$ 1,701	$ 3,513

STOCK-BASED COMPENSATION (Detai

STOCK-BASED COMPENSATION (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016
Employee stock option
Stock-based compensation
Stock-based compensation expense, net of estimated forfeitures, related to unvested awards not yet recognized	$ 2,858		$ 2,858
Stock-based compensation expense	$ 310	$ 578	$ 901
Weighted average remaining recognition period			1 year 7 months 7 days
Options
Stock Options, Number of Shares [Roll Forward]
Outstanding at the beginning of the period (in shares)			904,133
Granted (in shares)			55,000
Exercised (in shares)			0
Forfeited (in shares)			(808)
Expired (in shares)			(13,315)
Outstanding at the end of the period (in shares)	945,010		945,010
Options exercisable at the end of the period (in shares)	677,609		677,609
Stock Options, Weighted Average Exercise Price [Roll Forward]
Outstanding at the beginning of the period (in dollars per share)			$ 26.58
Granted (in dollars per share)			1.34
Exercised (in dollars per share)			0
Forfeited (in dollars per share)			5.97
Expired (in dollars per share)			38.20
Outstanding at the end of the period (in dollars per share)	$ 24.97		24.97
Options exercisable at the end of the period (in dollars per share)	$ 32.31		$ 32.31

STOCK-BASED COMPENSATION - REST

STOCK-BASED COMPENSATION - RESTRICTED STOCK UNIT ACTIVITY TABLE (Details) - Restricted stock units - shares	Sep. 10, 2015	Apr. 01, 2015	Jan. 02, 2014	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Outstanding at December 31, 2014 (in shares)				1,286,773
Awarded (in shares)				0
Released (in shares)				(454,131)
Forfeited (in shares)				(113,900)
Outstanding at June 30, 2015 (in shares)				718,742
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Weighted Average Remaining Contractual Life (years)				1 year 8 months 30 days
Ending vested and expected to vest (in shares)				611,510
Ending vested and expected to vest - Weighted average remaining contractual life				1 year 8 months 16 days
Weighted average remaining recognition period				2 years 8 months 30 days
Chief Executive Officer [Member]
Stock-based compensation
Vesting period			3 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Awarded (in shares)			100,000
Executive Employees [Member]
Stock-based compensation
Vesting period				4 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Awarded (in shares)		203,967		906,806
Non-Executive Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Awarded (in shares)	81,250

COMMITMENTS AND CONTINGENCIES C

COMMITMENTS AND CONTINGENCIES Commitments and Contingencies (Details)	3 Months Ended	6 Months Ended
	Jun. 30, 2016USD ($)	Jun. 30, 2016USD ($)	Jan. 20, 2016ft²	Jul. 01, 2015USD ($)	May 31, 2015USD ($)
Other Commitments [Line Items]
Area of Real Estate Property | ft²			30,000
Operating Leases, Future Minimum Payments Due, Next Twelve Months	$ 185,138	$ 185,138
Operating Leases, Future Minimum Payments, Due in Two Years	724,505	724,505
Operating Leases, Future Minimum Payments, Due in Three Years	784,983	784,983
Operating Leases, Future Minimum Payments, Due Thereafter	7,346,256	7,346,256
Security Deposit	307	307
operating leases, landlord reimbursement for lease improvements	889
operating leases, landlord reimb for lease improvements, additional payments	444
Incentive to Lessee	1,322	1,322
Quarterly fixed service fee	$ 520	520
Prepayment Fees on Advances, Net		$ 167
New Contractual Commitment
Other Commitments [Line Items]
Quarterly fixed service fee				$ 600,000
Prepayment against future fixed service fees					$ 1,000,000

GEOGRAPHIC INFORMATION - Schedu

GEOGRAPHIC INFORMATION - Schedule of distribution of revenues and long-lived assets (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Geographic Information
Revenue	$ 2,793	$ 744	$ 3,468	$ 1,389
U.S.
Geographic Information
Revenue	2,793	744	3,468	1,388
Canada
Geographic Information
Revenue	215	203	427	403
Operating segments
Geographic Information
Revenue	2,793	744	3,468
Operating segments | U.S.
Geographic Information
Revenue	2,793	744	3,468	1,388
Operating segments | Canada
Geographic Information
Revenue	0	0	0	1
Operating segments | Intersegment eliminations
Geographic Information
Revenue		0	0
Inter-geographic revenues | Canada
Geographic Information
Revenue	215	203
Inter-geographic revenues | Intersegment eliminations
Geographic Information
Revenue	(215)	(203)	(427)	(402)
Intersegment eliminations
Geographic Information
Revenue	$ (215)	$ (203)	(427)	(402)
Intersegment eliminations | U.S.
Geographic Information
Revenue			0
Intersegment eliminations | Canada
Geographic Information
Revenue			$ 427	$ 402

GEOGRAPHIC INFORMATION - Sche37

GEOGRAPHIC INFORMATION - Schedule of geographic distribution (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Geographic Information
Long-lived assets	$ 2,577	$ 905
U.S.
Geographic Information
Long-lived assets	2,577	903
Canada
Geographic Information
Long-lived assets	$ 0	$ 2

GEOGRAPHIC INFORMATION (Narrati

GEOGRAPHIC INFORMATION (Narrative) (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2016USD ($)customer	Jun. 30, 2015USD ($)
Concentration risk
Revenue earned from the REFABB grant	$ 188	$ 470	$ 345	$ 922
US Department of energy | Sales
Concentration risk
Revenue earned from the REFABB grant	$ 142	$ 347	$ 677
Concentration risk (as a percent)	5.00%	47.00%
Customer one | Sales
Concentration risk
Concentration risk (as a percent)			10.00%
Number of customers | customer			0

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Unrecognized tax benefits	$ 0	$ 0

RELATED PARTIES (Details)

RELATED PARTIES (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Related party transactions
Due from related party	$ 28		$ 28		$ 146
Tepha Inc | Affiliated entity
Related party transactions
Deferred Revenue, Additions	494
Tepha Inc | License revenue | Affiliated entity
Related party transactions
Revenue from related parties	1,580	$ 0	1,778	$ 0
Due from related party	$ 0		$ 0		$ 146

CAPITAL STOCK (Details)

CAPITAL STOCK (Details)	Oct. 07, 2015USD ($)$ / sharesshares	Jun. 19, 2015USD ($)shares$ / shares$ / warrant	May 26, 2015shares	Jun. 30, 2015USD ($)	Jun. 30, 2016USD ($)shares	Dec. 31, 2015USD ($)shares	May 25, 2015shares
Stock Purchase Agreement, Default, Stock Price Trigger | $ / shares	$ 0.50
Stock Issued During Period, Shares, New Issues	300,000
Deferred cost of product revenue | $					$ 58,000	$ 51,000
Common Stock Issuances
Common stock, shares outstanding			23,000,000		26,981,214	22,530,322	136,000,000
Proceeds from private placement offerings, net of issuance costs | $		$ 14,703,000		$ 15,000,000	$ 0
Common stock shares authorized			250,000,000		250,000,000	250,000,000
Issuance costs from private placement | $		$ 297,000
Unit price (in dollars per share) | $ / warrant		0.125
Class of Warrant or Right Expiration Term		4 years
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 3.98
Common stock, shares issued					26,981,214	22,530,322
Preferred shares issued					0	0
Common stock conversion ratio for each preferred stock			0.1667
Common stock
Common Stock Issuances
Number of units purchased		4,370,000
Share Price | $ / shares		$ 3.32
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		3,933,000
Aspire [Member] | Private Placement [Member]
Other Commitment | $	$ 20,000,000
Term of contractual service agreement	30 months
Aspire [Member]
Stock Issued | $	$ 450,000
Other Assets [Member] | Aspire [Member]
Deferred cost of product revenue | $	$ 169,000

SUBSEQUENT EVENT non-cash accel

SUBSEQUENT EVENT non-cash accelerated depreciation (Details) $ in Thousands	3 Months Ended
	Jun. 30, 2016USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Number of Positions Eliminated	45
Restructuring Charges	$ 4

SUBSEQUENT EVENT Restructuring

SUBSEQUENT EVENT Restructuring charges (Details)	3 Months Ended
	Jun. 30, 2016USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Number of Positions Eliminated	45
Restructuring Charges	$ 4,000
Restructuring and Related Cost, Accelerated Depreciation	$ 600